skip to main content
Global Search Configuration

Immunotherapies are one of the fastest growing treatment algorithms in pharma at the moment, and non-small cell lung cancer (NSCLC) is just one area of oncology that is going to make the transition into being dominated by this type of therapy. Not only that, but this focus will help to triple the value of the NSCLC market by 2023.

Our newest infographic will allow you to explore the key events up to 2023 that will make immunotherapies a key treatment type in NSCLC, and the key players in this field.

What will you learn from this infographic?


  • How PD-1/PD-L1 inhibitors is forecast to overtake EGFR inhibitors as the most commercially successful treatment type in NSCLC


  • Which of the five PD-1/PD-L1 inhibitors set to launch by 2023 is forecast to lead the ways in sales and why?


  • The key launch dates of immunotherapies over the next four years you’ll need to look out for





Download now

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: